Ischemic bowel disease is a life-threatening condition, and mortality will worsen if the patient presented in septic shock. Several factors affect the outcome of this disease. Recent data suggests, however, that patients who develop shock secondary to ischemic bowel and have a history of taking anti-platelet medications within two weeks of presentation may have a higher chance of survival when compared to a patient who did not. The study aims to determine the impaction of prophylactic anti-platelet (Aspirin and clopidogrel) administration in improving outcomes among patients who present with septic shock secondary to ischemic bowel. It was a retrospective cohort study conducted in all hospitals located in Winnipeg, Manitoba, Canada, from July 1989 until June 2007. 133 patients were presented in septic shock secondary to ischemic bowel. The primary outcome was survival to hospital discharge. Twenty-seven patients had a history of taking antiplatelet agent within two weeks before presentation, and 106 patients did not. Out of 27 of the patients who took antiplatelet agent, 15 patients survived, and 12 patients died with a mortality rate of 44%. Four patients had a history of taking dual anti-platelets (Aspirin and Clopidogrel) and all of them survived. Among the 106 patients who did not have a history of taking antiplatelet agent, only 19 patients survived with a mortality rate of 82%. This study investigates the impact of anti-platelet therapy in patients presenting to the emergency department and intensive care unit with and without prior use of antiplatelet therapy. Before presenting with septic shock secondary to ischemic bowel, patients who were on anti-platelet had a better chance to survive and got discharged home.